# Vistance Networks, Inc.: financial statements, quarterly VISN · Nasdaq · CIK 1517228 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/visn.md) · [Financials](/companies/visn/financials.md) · [Filings](/companies/visn/filings.md) · [Insiders](/companies/visn/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/visn/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1,053](/filings/0000950170-24-122512.md) | [923](/filings/0000950170-25-027196.md) | [901](/filings/0000950170-25-061257.md) | [1,054](/filings/0000950170-25-101615.md) | [1,082](/filings/0001193125-25-256715.md) | [415](/filings/0001193125-26-072523.md) | [388](/filings/0001193125-26-193963.md) | [324](/filings/0001193125-26-336708.md) | [1,630](/filings/0001193125-25-256715.md) | [515](/filings/0001193125-26-072523.md) | [472](/filings/0001193125-26-193963.md) | [320](/filings/0001193125-26-336708.md) | | Cost of revenue | $m | [673](/filings/0000950170-24-122512.md) | [(1,357) d](/filings/0001193125-26-072523.md) | [606](/filings/0000950170-25-061257.md) | [655](/filings/0000950170-25-101615.md) | [647](/filings/0001193125-25-256715.md) | [(1,130) d](/filings/0001193125-26-072523.md) | [191](/filings/0001193125-26-193963.md) | [176](/filings/0001193125-26-336708.md) | [962](/filings/0001193125-25-256715.md) | [(1,426) d](/filings/0001193125-26-072523.md) | [238](/filings/0001193125-26-193963.md) | [207](/filings/0001193125-26-336708.md) | | Gross profit | $m | [380](/filings/0000950170-25-027196.md) | [342](/filings/0000950170-25-027196.md) | [119](/filings/0001193125-26-072523.md) | [141](/filings/0001193125-26-072523.md) | [169](/filings/0001193125-26-072523.md) | [177](/filings/0001193125-26-072523.md) | [198](/filings/0001193125-26-193963.md) | [148](/filings/0001193125-26-336708.md) | [244](/filings/0001193125-26-072523.md) | [234](/filings/0001193125-26-072523.md) | [234](/filings/0001193125-26-193963.md) | [113](/filings/0001193125-26-336708.md) | | Research and development | $m | [85.4](/filings/0000950170-24-122512.md) | [20.9 d](/filings/0001193125-26-072523.md) | [84.6](/filings/0000950170-25-061257.md) | [72.6](/filings/0000950170-25-101615.md) | [78.0](/filings/0001193125-25-256715.md) | [12.3 d](/filings/0001193125-26-072523.md) | [66.2](/filings/0001193125-26-193963.md) | [43.1](/filings/0001193125-26-336708.md) | [95.3](/filings/0001193125-25-256715.md) | [13.4 d](/filings/0001193125-26-072523.md) | [58.2](/filings/0001193125-26-193963.md) | [30.8](/filings/0001193125-26-336708.md) | | Selling, general and administrative | $m | [186](/filings/0000950170-24-122512.md) | [(89.7) d](/filings/0001193125-26-072523.md) | [175](/filings/0000950170-25-061257.md) | [187](/filings/0000950170-25-101615.md) | [203](/filings/0001193125-25-256715.md) | [(93.5) d](/filings/0001193125-26-072523.md) | [109](/filings/0001193125-26-193963.md) | [79.7](/filings/0001193125-26-336708.md) | [227](/filings/0001193125-25-256715.md) | [(139) d](/filings/0001193125-26-072523.md) | [109](/filings/0001193125-26-193963.md) | [64.1](/filings/0001193125-26-336708.md) | | Operating income | $m | [(408)](/filings/0000950170-25-027196.md) | [(121)](/filings/0000950170-25-027196.md) | [(128)](/filings/0001193125-26-072523.md) | [(57.1)](/filings/0001193125-26-072523.md) | [(59.0)](/filings/0001193125-26-072523.md) | [(47.6)](/filings/0001193125-26-072523.md) | [(16.3)](/filings/0001193125-26-193963.md) | [7.8](/filings/0001193125-26-336708.md) | [18.7](/filings/0001193125-26-072523.md) | [(2.9)](/filings/0001193125-26-072523.md) | [23.7](/filings/0001193125-26-193963.md) | [(8.9)](/filings/0001193125-26-336708.md) | | Interest expense | $m | [171](/filings/0000950170-24-122512.md) | [171 d](/filings/0000950170-25-027196.md) | [168](/filings/0000950170-25-061257.md) | [168](/filings/0000950170-25-101615.md) | [168](/filings/0001193125-25-256715.md) | [184 d](/filings/0000950170-25-027196.md) | [174](/filings/0000950170-25-061257.md) | [0.0](/filings/0001193125-26-336708.md) | [155](/filings/0001193125-25-256715.md) | not reported | not reported | [0.8](/filings/0001193125-26-336708.md) | | Income tax | $m | [(34.5)](/filings/0000950170-24-122512.md) | [154 d](/filings/0001193125-26-072523.md) | [27.2](/filings/0000950170-25-061257.md) | [(12.4)](/filings/0000950170-25-101615.md) | [26.7](/filings/0001193125-25-256715.md) | [(109) d](/filings/0001193125-26-072523.md) | [(358)](/filings/0001193125-26-193963.md) | [2.5](/filings/0001193125-26-336708.md) | [42.6](/filings/0001193125-25-256715.md) | [(19.3) d](/filings/0001193125-26-072523.md) | [(185)](/filings/0001193125-26-193963.md) | [(28.7)](/filings/0001193125-26-336708.md) | | Net income | $m | [(829)](/filings/0000950170-25-027196.md) | [(581)](/filings/0000950170-25-027196.md) | [(334)](/filings/0001193125-26-072523.md) | [44.4](/filings/0001193125-26-072523.md) | [(33.0)](/filings/0001193125-26-072523.md) | [6.8](/filings/0001193125-26-072523.md) | [784](/filings/0001193125-26-193963.md) | [31.8](/filings/0001193125-26-336708.md) | [108](/filings/0001193125-26-072523.md) | [1,360](/filings/0001193125-26-072523.md) | [5,508](/filings/0001193125-26-193963.md) | [295](/filings/0001193125-26-336708.md) | | Diluted EPS | $ per share | [(3.98)](/filings/0000950170-24-122512.md) | not reported | [(1.65)](/filings/0000950170-25-061257.md) | [0.13](/filings/0000950170-25-101615.md) | [(0.23)](/filings/0001193125-25-256715.md) | not reported | [2.88](/filings/0001193125-26-193963.md) | [0.07](/filings/0001193125-26-336708.md) | [0.39](/filings/0001193125-25-256715.md) | not reported | [23.15](/filings/0001193125-26-193963.md) | [1.21](/filings/0001193125-26-336708.md) | | Basic EPS | $ per share | [(3.98)](/filings/0000950170-24-122512.md) | not reported | [(1.65)](/filings/0000950170-25-061257.md) | [0.13](/filings/0000950170-25-101615.md) | [(0.23)](/filings/0001193125-25-256715.md) | not reported | [3.55](/filings/0001193125-26-193963.md) | [0.07](/filings/0001193125-26-336708.md) | [0.41](/filings/0001193125-25-256715.md) | not reported | [24.45](/filings/0001193125-26-193963.md) | [1.25](/filings/0001193125-26-336708.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax - Cost of revenue: us-gaap:CostOfRevenue - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $bn | [0.5](/filings/0000950170-23-061320.md) | [0.5](/filings/0000950170-25-027196.md) | [0.4](/filings/0000950170-24-055965.md) | [0.3](/filings/0000950170-24-093045.md) | [0.4](/filings/0000950170-24-122512.md) | [0.4](/filings/0001193125-26-072523.md) | [0.5](/filings/0001193125-26-193963.md) | [0.6](/filings/0000950170-25-101615.md) | [0.7](/filings/0001193125-25-256715.md) | [0.6](/filings/0001193125-26-336708.md) | [2.5](/filings/0001193125-26-193963.md) | [0.1](/filings/0001193125-26-336708.md) | | Current assets | $bn | [3.2](/filings/0000950170-23-061320.md) | [2.8](/filings/0000950170-25-027196.md) | [2.4](/filings/0000950170-24-055965.md) | [2.6](/filings/0000950170-24-093045.md) | [3.4](/filings/0000950170-24-122512.md) | [3.5](/filings/0001193125-26-072523.md) | [2.3](/filings/0000950170-25-061257.md) | [2.5](/filings/0000950170-25-101615.md) | [2.8](/filings/0001193125-25-256715.md) | [5.8](/filings/0001193125-26-336708.md) | [3.3](/filings/0001193125-26-193963.md) | [1.9](/filings/0001193125-26-336708.md) | | Total assets | $bn | [10.1](/filings/0000950170-23-061320.md) | [9.3](/filings/0000950170-25-027196.md) | [8.7](/filings/0000950170-24-055965.md) | [8.8](/filings/0000950170-24-093045.md) | [8.8](/filings/0000950170-24-122512.md) | [8.7](/filings/0001193125-26-072523.md) | [7.5](/filings/0000950170-25-061257.md) | [7.7](/filings/0000950170-25-101615.md) | [7.9](/filings/0001193125-25-256715.md) | [9.4](/filings/0001193125-26-336708.md) | [5.4](/filings/0001193125-26-193963.md) | [3.5](/filings/0001193125-26-336708.md) | | Current liabilities | $bn | [1.5](/filings/0000950170-23-061320.md) | [1.4](/filings/0000950170-25-027196.md) | [1.0](/filings/0000950170-24-055965.md) | [2.5](/filings/0000950170-24-093045.md) | [2.5](/filings/0000950170-24-122512.md) | [1.2](/filings/0001193125-26-072523.md) | [1.0](/filings/0000950170-25-061257.md) | [1.2](/filings/0000950170-25-101615.md) | [1.2](/filings/0001193125-25-256715.md) | [1.5](/filings/0001193125-26-336708.md) | [0.5](/filings/0001193125-26-193963.md) | [0.7](/filings/0001193125-26-336708.md) | | Total liabilities | $bn | [11.4](/filings/0000950170-23-061320.md) | [11.2](/filings/0000950170-25-027196.md) | [10.8](/filings/0000950170-25-027196.md) | [11.0](/filings/0000950170-25-027196.md) | [11.0](/filings/0000950170-25-027196.md) | [11.0](/filings/0001193125-26-072523.md) | [8.8](/filings/0000950170-25-061257.md) | [8.9](/filings/0000950170-25-101615.md) | [9.0](/filings/0001193125-25-256715.md) | [9.1](/filings/0001193125-26-336708.md) | [0.8](/filings/0001193125-26-193963.md) | [1.0](/filings/0001193125-26-336708.md) | | Long-term debt | $bn | [9.4](/filings/0000950170-23-061320.md) | [9.2](/filings/0000950170-25-027196.md) | [9.2](/filings/0000950170-24-055965.md) | [8.0](/filings/0000950170-24-093045.md) | [8.0](/filings/0000950170-24-122512.md) | [9.2](/filings/0001193125-26-072523.md) | [7.2](/filings/0000950170-25-061257.md) | [7.2](/filings/0000950170-25-101615.md) | [7.3](/filings/0001193125-25-256715.md) | [7.3](/filings/0001193125-26-336708.md) | [0.0](/filings/0001193125-26-193963.md) | [0.0](/filings/0001193125-26-336708.md) | | Current portion of debt | $bn | [0.0](/filings/0000950170-24-055965.md) | [0.0](/filings/0000950170-25-027196.md) | [0.0](/filings/0000950170-24-055965.md) | [1.3](/filings/0000950170-24-093045.md) | [1.3](/filings/0000950170-24-122512.md) | [0.0](/filings/0001193125-26-072523.md) | [0.0](/filings/0000950170-25-061257.md) | [0.0](/filings/0000950170-25-101615.md) | [0.0](/filings/0001193125-25-256715.md) | [0.0](/filings/0001193125-26-336708.md) | [0.0](/filings/0001193125-26-193963.md) | [0.0](/filings/0001193125-26-336708.md) | | Shareholders' equity | $bn | [(2.5)](/filings/0000950170-24-122512.md) | [(3.0)](/filings/0001193125-26-072523.md) | [(3.4)](/filings/0000950170-25-061257.md) | [(3.3)](/filings/0000950170-25-101615.md) | [(3.4)](/filings/0001193125-25-256715.md) | [(3.5)](/filings/0001193125-26-072523.md) | [(2.5)](/filings/0001193125-26-193963.md) | [(2.4)](/filings/0001193125-26-336708.md) | [(2.3)](/filings/0001193125-25-256715.md) | [(1.0)](/filings/0001193125-26-336708.md) | [4.6](/filings/0001193125-26-193963.md) | [2.5](/filings/0001193125-26-336708.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [139 d](/filings/0000950170-24-122512.md) | [67.8 d](/filings/0001193125-26-072523.md) | [(178)](/filings/0000950170-25-061257.md) | [50.8 d](/filings/0000950170-25-101615.md) | [122 d](/filings/0001193125-25-256715.md) | [278 d](/filings/0001193125-26-072523.md) | [(187)](/filings/0001193125-26-193963.md) | [77.1 d](/filings/0001193125-26-336708.md) | [151 d](/filings/0001193125-25-256715.md) | [281 d](/filings/0001193125-26-072523.md) | [(227)](/filings/0001193125-26-193963.md) | [(72.8) d](/filings/0001193125-26-336708.md) | | Capital expenditure | $m | [8.7](/filings/0000950170-23-061320.md) | [16.8 d](/filings/0001193125-26-072523.md) | [6.0](/filings/0000950170-25-061257.md) | [5.3 d](/filings/0000950170-25-101615.md) | [6.7 d](/filings/0001193125-25-256715.md) | [7.3 d](/filings/0001193125-26-072523.md) | [15.5](/filings/0001193125-26-193963.md) | [12.6 d](/filings/0001193125-26-336708.md) | [16.4 d](/filings/0001193125-25-256715.md) | [25.8 d](/filings/0001193125-26-072523.md) | [2.2](/filings/0001193125-26-193963.md) | [2.0 d](/filings/0001193125-26-336708.md) | | Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Dividends paid: not reported - Share repurchases: not reported ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [0.0](/filings/0000950170-23-061320.md) | [212](/filings/0000950170-24-055965.md) | [211](/filings/0000950170-24-093045.md) | [212](/filings/0000950170-24-122512.md) | [212](/filings/0000950170-25-061257.md) | [214](/filings/0000950170-25-101615.md) | [216](/filings/0001193125-25-256715.md) | [272](/filings/0001193125-26-193963.md) | [218](/filings/0001193125-26-336708.md) | [278](/filings/0001193125-25-256715.md) | [238](/filings/0001193125-26-193963.md) | [234](/filings/0001193125-26-336708.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 230,626,412 at 2026-07-22, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-336708.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.